Is retatrutide the same as tirzepatide?

No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.

Is retatrutide approved anywhere?

No. As of 2026 retatrutide has not been approved by any regulator worldwide. It remains an investigational compound.

What does LY3437943 mean?

It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.

Retatrutide Research

What Is Retatrutide? Complete Research Overview

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-07-033 cited sources

Retatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.

Key facts

Chemical name: LY3437943 (Retatrutide)
Class: Triple receptor agonist (GIP/GLP-1/Glucagon)
Molecular weight: ~4,731 Da
Developer: Eli Lilly and Company
Status: Investigational — Phase 3 (TRIUMPH programme)
Approval: Not approved by FDA, EMA, or MHRA

What is retatrutide chemically?

Retatrutide is a 39-amino-acid synthetic peptide analogue derived from the GIP scaffold, engineered with fatty-acid conjugation to extend its plasma half-life. It is a single-molecule triple agonist — one peptide chain that binds three distinct incretin family receptors at physiologically relevant concentrations.

Who developed retatrutide?

Retatrutide is being developed by Eli Lilly and Company under the internal code LY3437943. The programme sits alongside Lilly's earlier incretin work on dulaglutide (Trulicity) and tirzepatide (Mounjaro / Zepbound), and represents the next generation beyond dual GIP/GLP-1 agonism.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What is its regulatory status?

As of 2026 retatrutide is an investigational compound. It has not received marketing authorisation from the FDA, EMA, or MHRA, and is available only within clinical-trial and research settings. It is progressing through the Phase 3 TRIUMPH programme.

Why is it studied?

Published Phase 2 data in the New England Journal of Medicine (Jastreboff et al., 2023) reported the largest weight reductions observed to date for any single-molecule incretin agonist. This has made retatrutide a widely referenced compound in metabolic pharmacology research literature.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals — research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is retatrutide the same as tirzepatide?: No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.
Is retatrutide approved anywhere?: No. As of 2026 retatrutide has not been approved by any regulator worldwide. It remains an investigational compound.
What does LY3437943 mean?: It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum